Tauopathies are a group of progressive neurological diseases caused by the accumulation of misfolded tau proteins in the brain. These diseases, which include Alzheimer’s disease and some forms of frontotemporal dementia, are characterized by neuron death and subsequent cognitive and physical decline. Tauopathies are difficult to diagnose and have no known cure; current treatments are mainly palliative. Tau proteins are a class of proteins found in the cytoskeleton of neurons, and are involved in the maintenance of neuronal structure and communication. In healthy cells, tau proteins ensure that the microtubules in a neuron remain stable. In individuals with tauopathies, however, these proteins become misfolded and form accumulations, known as neurofibrillary tangles, around the neuron’s nucleus. As these tau aggregates form, they interfere with the ability of a neuron to transport and process signals. The neurons are effectively ‘clogged up’, and eventually die. As this process continues throughout the brain, it has debilitating effects on cognitive and physical abilities. Due to the complexity of the disease, quality of care is often an issue in tauopathies. Diagnosis can be difficult, since the symptoms of tauopathy diseases can vary from person to person. Furthermore, the development of treatments has been hindered by the difficulty in studying tau accumulation in living brains. There are also ethical concerns in experiments that involve the study of tau pathology in live cells, since the process of accumulation can be slow, making results hard to observe over a viable timescale. Despite these constraints, researchers have made progress in the understanding and treatment of tauopathies, including the development of monoclonal antibodies and other therapies. In conclusion, tauopathies are a group of neurological diseases caused by the misfolding of tau proteins, which disrupt signal transmission and cause neuron death. Current treatments are mainly palliative, and further research is needed to develop effective diagnostic and treatment methods.
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : ADNP regulates cortical development: Mechanism of ADNP syndrome/autism
Kazuhito Toyooka, Drexel University College of Medicine, United States
Title : Mild cognitive impairment (MCI) in Parkinson’s disease: Prevalence given MDS criteria
Cay Anderson Hanley, iPACES, United States
Title : Modeling early neurologic trajectories after elevated leg positioning (ELP): A secondary analysis of the LEG-UP randomized feasibility study
Kayode Ahmed, The University of Texas MD Anderson Cancer Center, United States
Title : Neuro-exergaming for non-verbal autism spectrum: A case study of neuropsychological function after 15 sessions of pedal-n-play iPACES
Cay Anderson Hanley, iPACES, United States
Title : Prescribing joy: The importance of integrating memory cafes into dementia care
Saul Beaumont, Massachusetts Advisory Council on Alzheimer's Disease and All Other Dementias, United States